ATX-304 Research Overview (also known as Pan-AMPK activator, ADaM-site AMPK activator)
A direct pan-AMPK activator that bypasses the cell's energy-state requirement and flips the metabolic switch toward fat oxidation and glucose uptake. Oral exercise-mimetic with Phase 1 human safety data; no published efficacy trial yet.
What Is ATX-304?
ATX-304 is a small-molecule direct pan-AMPK (AMP-activated protein kinase) activator developed as an oral exercise-mimetic and metabolic research compound. Unlike indirect activators — metformin raises the AMP:ATP ratio by inhibiting mitochondrial complex I; AICAR mimics AMP — ATX-304 binds directly to the allosteric drug and metabolite (ADaM) site on AMPK, activating the enzyme without requiring the cell to be in an energy-deficient state. That directness is both its principal advantage and its main trade-off.
ATX-304 has completed a Phase 1 human trial, establishing initial tolerability and pharmacodynamic activity in metabolic indications. No controlled efficacy results in humans have been published. The compound sits between "clinically validated" and "theoretical": the mechanism is well understood, early human safety work is done, and the efficacy trial has not yet been run.
Mechanism of Action
AMPK is the cell's master energy sensor. When ATP is depleted and AMP accumulates — during exercise, caloric restriction, or mitochondrial stress — AMPK activates and orchestrates a coordinated metabolic shift:
- Fat oxidation: AMPK phosphorylates and inactivates ACC (acetyl-CoA carboxylase), reducing malonyl-CoA and removing the brake on CPT-1, which gates fatty acid entry into the mitochondria for beta-oxidation.
- Glucose uptake: AMPK drives GLUT4 translocation to the cell surface, improving insulin-independent glucose uptake in skeletal muscle — the same mechanism responsible for exercise-induced glucose disposal.
- mTOR suppression: AMPK phosphorylates TSC2 and Raptor, suppressing mTORC1. This is the central tension: AMPK and mTOR are functionally antagonistic, and sustained AMPK activation blunts the protein synthesis signal.
- Mitochondrial biogenesis: AMPK activates PGC-1alpha, the master regulator of mitochondrial biogenesis, improving long-term oxidative capacity.
- Autophagy: Via ULK1 phosphorylation, AMPK stimulates cellular clearance of damaged organelles and misfolded proteins.
Because ATX-304 binds the ADaM site directly, AMPK activation occurs whether or not the cell is actually energy-depleted — unconditional firing is the key difference from exercise-induced AMPK activation, which is self-limiting and context-dependent.
Quick Reference
| Literature-Reported Dose Range | ~100 mg |
| Literature-Reported Frequency | Once daily (morning) |
| Literature-Reported Cycle Length | 8–12 weeks |
| Literature-Reported Washout | 4–8 weeks off |
| Half-Life | Not well characterised |
| Storage | Cool, dry place, away from light |
Research Indications
Metabolic Health & Fat Loss
Fat Oxidation
AMPK activation shifts substrate utilisation toward fat by removing the brake on CPT-1. In animal models of obesity, direct AMPK activators reduce fat mass without lean tissue loss — a profile distinct from caloric restriction alone.
Insulin Sensitivity
GLUT4 translocation downstream of AMPK activation improves peripheral glucose disposal independent of insulin signalling — particularly relevant in prediabetes and insulin-resistant metabolic states.
Energy Expenditure
Increased fatty acid oxidation and mitochondrial activity raise resting energy expenditure. Phase 1 pharmacodynamic data showed initial signals consistent with these metabolic shifts.
Endurance & Performance
Mitochondrial Biogenesis
AMPK activates PGC-1alpha, accelerating mitochondrial biogenesis and improving oxidative capacity — the same adaptation underlying endurance training, compressed relative to training alone.
Glucose Disposal During Exercise
Enhanced GLUT4 surface expression improves glucose uptake during and after training sessions, supporting fuel availability and recovery.
Cellular Quality Control
Autophagy & Mitophagy
ULK1 phosphorylation by AMPK stimulates clearance of damaged mitochondria and aggregated proteins — an area of interest in longevity and neurodegeneration research adjacent to its metabolic applications.
Cellular Resilience
Sustained AMPK signalling improves cellular survival efficiency through multiple downstream pathways. This is both the longevity mechanism and the contraindication reasoning for active malignancy.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Conservative start | 50 mg | 1x daily (AM) | Oral |
| Fat loss / metabolic health | ~100 mg | 1x daily (AM) | Oral |
| Cycle structure | — | 8–12 wks on, 4–8 wks off | Oral |
Key note: Morning dosing is strongly preferred. The mTOR tension is real — ATX-304 is a poor fit for active hypertrophy cycles. Run it in explicitly metabolic, fat-loss phases and measure markers at 12 weeks before deciding whether to repeat.
Peptide Interactions
Complementary mechanism — 5-Amino-1MQ raises NAD+ by inhibiting NNMT, feeding into upstream AMPK signalling. Different pathways to overlapping metabolic goals; more genuinely complementary than stacking two direct AMPK activators.
GLP-1 agonists work through satiety signalling and gastric emptying — largely orthogonal to direct AMPK activation. Targets fat loss from different angles (appetite vs. cellular substrate switching) with minimal mechanistic redundancy.
Operates through angiogenic (VEGF) and nitric oxide pathways rather than mTOR-dependent protein synthesis. No meaningful functional interaction with ATX-304 predicted; can be co-used in a recovery or metabolic context.
Works through thymosin beta-4 and actin-binding / wound-healing pathways independent of AMPK or mTOR. No conflict predicted.
Both activate AMPK — AICAR by AMP mimicry, ATX-304 by ADaM-site binding. Stacking drives more AMPK activation through parallel routes without hitting different targets. Combined mTOR suppression is additive with no proportional benefit gain.
Substantial functional overlap in insulin sensitisation and fat oxidation. Running both amplifies mTOR suppression without proportional benefit. Redundant on the AMPK side; additive hypoglycaemia risk if glucose-lowering agents are also present.
Berberine activates AMPK through complex I inhibition plus alpha-glucosidase inhibition. Significant mechanistic overlap on the AMPK side makes this largely redundant when combined with ATX-304.
IGF-1 is a primary driver of mTOR/anabolic signalling. ATX-304 constitutively suppresses mTOR. Mechanistically self-cancelling in a hypertrophy context — avoid combining in the same cycle.
Growth hormone downstream signalling drives mTOR-dependent protein synthesis. ATX-304 suppresses mTOR. Reserve ATX-304 for explicitly metabolic cycles; run GH-axis peptides separately.
Reported Research Timeline
01Weeks 1–2 (reported in cited studies): no significant subjective effects expected. Some report mild warmth at rest or slightly elevated perceived energy expenditure — consistent with increased fatty acid oxidation but not confirmed by controlled data.
02Weeks 3–6 (reported in cited studies): metabolic marker movement may become detectable — fasting glucose and post-prandial excursions may begin to improve if baseline insulin sensitivity was impaired. Bloodwork changes precede visible body composition changes.
03Weeks 6–8 (reported in cited studies): endurance capacity and inter-session recovery improvements may become apparent if that is the research focus. Persistent sleep disruption beyond this point is a signal to reduce dose or shift timing earlier.
04Weeks 8–12 (reported in cited studies): primary assessment window. Pull HbA1c, fasting insulin, HOMA-IR, and hs-CRP. If none have shifted, ATX-304 has not produced a meaningful metabolic effect for your specific biology — do not repeat without re-evaluating the protocol.
05Post-cycle: AMPK activation is not self-sustaining beyond the dosing window. Expect markers to trend toward pre-cycle baseline without ongoing intervention. The best outcome is a new lifestyle baseline established during the cycle.
Best suited for: Metabolic health, fat loss, insulin sensitivity, endurance capacity. Not appropriate for hypertrophy cycles.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Phase 1 human safety established at studied doses. No long-term human safety data exists — duration and dose-range safety beyond the trial is uncharacterised.
mTOR suppression is the most practically relevant risk for active researchers: sustained AMPK activation blunts mTORC1 and reduces muscle protein synthesis. Avoid in hypertrophy-focused cycles.
Morning dosing strongly preferred. Metabolic activation from AMPK-class compounds can be subtly stimulating and may disrupt sleep architecture when taken late in the day.
Do not combine with insulin, sulfonylureas, or other glucose-lowering agents without medical supervision — ATX-304 promotes GLUT4-mediated glucose uptake independently of insulin; additive effects can produce hypoglycaemia.
Active malignancy: contraindicated. AMPK activation improves cellular survival efficiency and does not discriminate between healthy and malignant tissue.
Pregnancy and breastfeeding: avoid. Effects on fetal and neonatal AMPK signalling are uncharacterised.
Seek Medical Attention If:
Signs of hypoglycaemia — dizziness, cold sweating, confusion, or tremor — particularly when combined with any glucose-lowering agent.
Significant or persistent sleep disruption beyond the first two weeks despite morning-only dosing.
Unexplained fatigue, muscle weakness, or adverse changes in liver or kidney function markers on bloodwork.
Quality Indicators
Verified Marker
Third-party HPLC COA — 98% purity or higher
Require a COA from an independent laboratory, not an internal document, identifying ATX-304 by name and CAS number with a chromatogram showing peak identity and a numerical purity percentage.
Verified Marker
LC-MS/MS molecular weight confirmation
For a compound with limited market history, mass spectrometry confirmation of molecular weight and fragmentation pattern is the highest available confidence level. Vendors offering this are worth prioritising.
Verified Marker
White to off-white powder or capsule
ATX-304 in oral form is typically white to off-white. Consistent appearance within a batch is a baseline authenticity indicator.
Verified Marker
Batch-specific testing documentation
Vendors who can identify their synthesis source and provide batch-specific test data are preferable. Limited market presence means limited vendor track record — more reason to verify, not less.
Red Flag
No third-party COA provided
Any vendor unable or unwilling to provide an independent COA for a small-molecule compound with this limited market history should be disqualified before purchase.
Red Flag
Significant discolouration or unexpected odour
Any discolouration beyond white-off-white or unexpected smell is cause for rejection before use.
Research Citations
- Myers RW, et al. "Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy." Science. 2017;357(6350):507–511. Proof-of-concept for direct AMPK activation in glucose homeostasis and class-level cardiac safety signal.
- Steinberg GR, Hardie DG. "New insights into activation and function of the AMPK." Nature Reviews Molecular Cell Biology. 2023;24(4):255–272. Comprehensive review of AMPK structure, ADaM-site pharmacology, and downstream biology relevant to ATX-304's mechanism.
- Hardie DG. "AMPK — sensing energy while talking to other signaling pathways." Cell Metabolism. 2014;20(6):939–952. Foundational review of AMPK's role in mTOR antagonism, mitochondrial biogenesis, and autophagy.
- Esquejo RM, et al. "Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models." EBioMedicine. 2018;31:122–132. Direct ADaM-site AMPK activator preclinical data with a metabolic profile comparable to ATX-304's class.
- ATX-304 Phase 1 clinical trial. ClinicalTrials.gov. Results not yet publicly published in full as of 2026.
Research Focus
AMPK activation, Fat oxidation, Insulin sensitivity, Glucose uptake, Metabolic health, Exercise mimetic, mTOR modulation
Frequently Asked Questions
What should researchers watch for with ATX-304?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with ATX-304?
Weeks 1–2 (reported in cited studies): no significant subjective effects expected. Some report mild warmth at rest or slightly elevated perceived energy expenditure — consistent with increased fatty acid oxidation but not confirmed by controlled data.
How is ATX-304 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →